| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President, Global Head of R&D | Global Head of R&D
1 company
Wang Lai is a President, Global Head of R&D at ONC. Recent filings cover 0 purchases and 46 sales.
Our model assigns Wang Lai a middling insider score of 50/100, based on 27 past trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -10.2%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 28, 2021 | ONC Beone Medicines Ltd. | Global Head of R&D | Sell | 455 | $362.48 | $164,929.95 | -100% | +5.4% | -53.9% | |
| Jun 18, 2021 | ONC Beone Medicines Ltd. | Global Head of R&D | Sell | 802 | $331.15 | $265,583.18 | -100% | +19.7% | -58.9% | |
| Jun 7, 2021 | ONC Beone Medicines Ltd. | Global Head of R&D | Sell | 656 | $354.26 | $232,392.33 | -100% | +0.7% | -55.1% |